Live intraday price
Compare with our price levels
Close 2026-09-30: $4.21 · Levels are calculated once a day from the closing price; live prices come from TradingView (may be delayed at times)
Not in the buy zone yet — needs to drop 15.0% · 1 whale recently bought
🎯 Trade plan by price level
Buy in 3 tranches in the buy zone · sell in 3 tranches at the targets · sell everything if the stop-loss breaks
Price levels and picks are calculated automatically with the same formula for every stock — for education only, not a recommendation to buy or sell. · How it's calculated
Risk : reward 1 : 3.1Moves ~$0.25 a day
⚖️ Positives and risks
- ●เซียนซื้อใหม่/ซื้อเพิ่มไตรมาสล่าสุด 1 ราย
- ●แข็งแกร่งกว่าตลาด (S&P 500) +18% ใน 6 เดือน
- ●ราคาเป้าหมายนักวิเคราะห์เฉลี่ย 7.22 (upside +71%, 6 ราย)
- ●นักวิเคราะห์ส่วนใหญ่แนะนำ Buy
- ●รายได้หดตัว -60% เทียบปีก่อน
🕯️ Price chart
Green lines = buy zone E1–E3 · orange = targets T1–T3 · red = stop-loss · arrows = where the paper-trading bot bought/sold
🐋 Whales holding this stock
From each whale's latest quarterly filing
👔 Insider buying & selling
Latest trades from SEC Form 4 filings
Khan Najat · CEO · Director
2026-09-08 · 22,408 shares @ $3.52 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-09-01 · 30,000 shares @ $3.34 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-08-04 · 30,000 shares @ $3.25 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-07-07 · 40,000 shares @ $3.96 · pre-planned sale (10b5-1)
Bumpus Namandje · Director
2026-06-18 · 3,963 shares @ $3.18 · pre-planned sale (10b5-1)
Gibson Christopher · Director
2026-06-05 · 40,000 shares @ $3.62 · pre-planned sale (10b5-1)
Khan Najat · CEO · Director
2026-06-05 · 23,588 shares @ $3.58 · pre-planned sale (10b5-1)
Bumpus Namandje · Director
2026-06-03 · 4,386 shares @ $3.54 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-06-02 · 30,000 shares @ $3.68 · pre-planned sale (10b5-1)
Gibson Christopher · Director
2026-05-22 · 40,000 shares @ $3.08 · pre-planned sale (10b5-1)
Gibson Christopher · Director
2026-05-07 · 40,000 shares @ $3.37 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-05-05 · 30,000 shares @ $3.52 · pre-planned sale (10b5-1)
Gibson Christopher · Director
2026-04-22 · 40,000 shares @ $3.61 · pre-planned sale (10b5-1)
Gibson Christopher · Director
2026-04-07 · 40,000 shares @ $3.10 · pre-planned sale (10b5-1)
Borgeson Blake · Director
2026-04-07 · 30,000 shares @ $3.10 · pre-planned sale (10b5-1)
💬 User reviews
Rate and review this stock (sign-in required) — reviews don't affect the system's scores
Loading…
Ratings and comments are each user's own opinion. They don't affect the Smart-Money Score, signals, or price levels and are not investment advice · The average counts each person's latest rating, one vote per person
📰 Latest news
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks · 2026-09-28
Analysts move HubSpot 29 places higher in power ranking
TheStreet · 2026-09-24
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Zacks · 2026-09-24
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
TechCrunch · 2026-09-23
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know
Zacks · 2026-09-22
🔬 Deep dive
For those who want the detailed numbers